Cagrilintide 10mg

Cagrilintide is a novel, long-acting acylated amylin analogue developed to mimic and extend the physiological actions of human amylin (islet amyloid polypeptide, IAPP). Unlike native amylin, cagrilintide features structural modifications and a fatty acid side chain that confer exceptional pharmacokinetic stability, enabling prolonged receptor occupancy at amylin and calcitonin receptors. This sustained activity makes it a valuable tool in preclinical research focused on energy balance, satiety signalling, and glucose homeostasis.

In research settings, cagrilintide has been studied extensively in the context of metabolic syndrome, obesity, and type 2 diabetes models. Its mechanism of action involves agonism at amylin receptor complexes (comprising calcitonin receptor subunits and receptor activity-modifying proteins), resulting in delayed gastric emptying, suppression of glucagon secretion, and central modulation of appetite via hypothalamic pathways. When investigated in combination with GLP-1 receptor agonists such as semaglutide, synergistic effects on body weight reduction and glycaemic control have been observed in preclinical and clinical study data.

Specifications: Molecular Formula: C₁₆₇H₂₆₄N₄₄O₅₅S (base peptide backbone, acylated analogue); Molecular Weight: approximately 3916.4 g/mol; Purity: >98% by HPLC; CAS Number: 2413968-35-9; Form: Lyophilised Powder. Store at -20°C, protected from light and moisture. Reconstitute in sterile bacteriostatic water or suitable solvent prior to use.

For research purposes only. Not for human use.